Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
United States
Children's National Hospital, Washington D.C., District of Columbia Johns Hopkins University, Baltimore, Maryland National Institutes of Health (NIH), Bethesda, Maryland